Age-related pharmacokinetics differences were observed between young and elderly populations of a novel PDE5 inhibitor, youkenafil, and its metabolite M459-Reference-Cited by-同舟云学术

Age-related pharmacokinetics differences were observed between young and elderly populations of a novel PDE5 inhibitor, youkenafil, and its metabolite M459

Published:2024-05 Issue: Volume:196 Page:106755
ISSN:0928-0987
Container-title:European Journal of Pharmaceutical Sciences
language:en
Short-container-title:European Journal of Pharmaceutical Sciences

Author:

Lin Yuhong,Long Yao,Wang Yaqin,Wang Lin,Wang Minhui,Xia Xiaocui,Chen Xinyan,Huang Yunzhe,Du Pengfei,Wu Jianbang,Jia Yuanwei,Shen Jie

Publisher

Elsevier BV

Reference31 articles.

1. PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery;Andersson;Br. J. Pharmacol.,2018

2. Technical Guidelines of Clinical Single- and Multiple-ascending Doses Pharmacokinetic Studies for Chemical Innovative Drugs (in Chinese),2021

3. Yonkenafil: a novel phosphodiesterase type 5 inhibitor induces neuronal network potentiation by a cGMP-dependent Nogo-R axis in acute experimental stroke;Chen;Exp. Neurol.,2014

4. Male sexual dysfunction: a review of literature on its pathological mechanisms, potential risk factors, and herbal drug intervention;Chen;Biomed. Pharmacother.,2019

5. Quantification of cefaclor in human plasma using SIL-IS LC-ESI-MS/MS for pharmacokinetics study in healthy Chinese volunteers;Chen;Biomed. Chromatogr.,2023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SIL‐IS LC–ESI–MS/MS method for simultaneous quick detection of amoxicillin and clavulanic acid in human plasma: Development, validation and its application to a pharmacokinetics study;Biomedical Chromatography;2024-09-10